Literature for mupain-1 (S01.231 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. Wang,D., Yang,Y., Jiang,L., Wang,Y., Li,J., Andreasen,P.A., Chen,Z., Huang,M. and Xu,P.
   Suppression of tumor growth and metastases by targeted intervention in urokinase activity with cyclic peptides
   J Med Chem62, 2172-2183. PubMed  Europe PubMed DOI  I
2017
2. Xu,P., Andreasen,P.A. and Huang,M.
   Structural principles in the development of cyclic peptidic enzyme inhibitors
   Int J Biol Sci13, 1222-1233. PubMed  Europe PubMed DOI  I
2015
3. Xu,P., Xu,M., Jiang,L., Yang,Q., Luo,Z., Dauter,Z., Huang,M. and Andreasen,P.A.
   Design of specific serine protease inhibitors based on a versatile peptide scaffold: conversion of a urokinase inhibitor to a plasma kallikrein inhibitor
   J Med Chem58, 8868-8876. PubMed  Europe PubMed DOI  I
2014
4. Zhao,B., Xu,P., Jiang,L., Paaske,B., Kromann-Hansen,T., Jensen,J.K., Sorensen,H.P., Liu,Z., Nielsen,J.T., Christensen,A., Hosseini,M., Sorensen,K.K., Nielsen,N.C., Jensen,K.J., Huang,M. and Andreasen,P.A.
   A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility
   PLoS ONE9, e115872-e115872. PubMed  Europe PubMed DOI  S  I
2011
5. Hosseini,M., Jiang,L., Sorensen,H.P., Jensen,J.K., Christensen,A., Fogh,S., Yuan,C., Andersen,L.M., Huang,M., Andreasen,P.A. and Jensen,K.J.
   Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs
   Mol Pharmacol80, 585-597. PubMed  Europe PubMed DOI  I
2008
6. Andersen,L.M., Wind,T., Hansen,H.D. and Andreasen,P.A.
   A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue
   Biochem J412, 447-457. PubMed  Europe PubMed DOI  I